HK1244006A1 - Parp抑制剂的结晶形式 - Google Patents

Parp抑制剂的结晶形式 Download PDF

Info

Publication number
HK1244006A1
HK1244006A1 HK18103530.1A HK18103530A HK1244006A1 HK 1244006 A1 HK1244006 A1 HK 1244006A1 HK 18103530 A HK18103530 A HK 18103530A HK 1244006 A1 HK1244006 A1 HK 1244006A1
Authority
HK
Hong Kong
Prior art keywords
compound
crystalline form
depicted
further characterized
diffraction pattern
Prior art date
Application number
HK18103530.1A
Other languages
English (en)
Chinese (zh)
Inventor
Stephen J. BIERLMAIER
Ralph C. HALTIWANGER
Martin J. Jacobs
Original Assignee
赛福伦公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 赛福伦公司 filed Critical 赛福伦公司
Publication of HK1244006A1 publication Critical patent/HK1244006A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/06—Glycolic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK18103530.1A 2014-11-26 2015-11-25 Parp抑制剂的结晶形式 HK1244006A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084652P 2014-11-26 2014-11-26
US62/084,652 2014-11-26
PCT/US2015/062572 WO2016086080A1 (en) 2014-11-26 2015-11-25 Crystalline forms of parp inhibitors

Publications (1)

Publication Number Publication Date
HK1244006A1 true HK1244006A1 (zh) 2018-07-27

Family

ID=54849709

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103530.1A HK1244006A1 (zh) 2014-11-26 2015-11-25 Parp抑制剂的结晶形式

Country Status (13)

Country Link
US (1) US10150772B2 (enExample)
EP (1) EP3224259A1 (enExample)
JP (1) JP2017535564A (enExample)
KR (1) KR20170088894A (enExample)
CN (1) CN107207511A (enExample)
AU (1) AU2015353549A1 (enExample)
BR (1) BR112017010588A2 (enExample)
CA (1) CA2967828A1 (enExample)
HK (1) HK1244006A1 (enExample)
IL (1) IL252162A0 (enExample)
MX (1) MX2017006679A (enExample)
RU (1) RU2017120655A (enExample)
WO (1) WO2016086080A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US20060276497A1 (en) 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
WO2008063644A1 (en) * 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent
JP2013503173A (ja) * 2009-08-26 2013-01-31 セファロン、インク． 多環系化合物の新規形態

Also Published As

Publication number Publication date
JP2017535564A (ja) 2017-11-30
CN107207511A (zh) 2017-09-26
BR112017010588A2 (pt) 2018-05-15
US10150772B2 (en) 2018-12-11
MX2017006679A (es) 2018-07-06
WO2016086080A1 (en) 2016-06-02
EP3224259A1 (en) 2017-10-04
CA2967828A1 (en) 2016-06-02
IL252162A0 (en) 2017-07-31
RU2017120655A3 (enExample) 2018-12-14
KR20170088894A (ko) 2017-08-02
US20170267683A1 (en) 2017-09-21
AU2015353549A1 (en) 2017-06-01
RU2017120655A (ru) 2018-12-14

Similar Documents

Publication Publication Date Title
AU2016204294B9 (en) Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor
JP2020536893A (ja) ロルラチニブ遊離塩基水和物の結晶形態
US10206916B2 (en) Cabozantinib salts and their use as anti-cancer agents
US20160354351A1 (en) Solid state forms of vemurafenib hydrochloride
JP2018035158A (ja) 多環系化合物の新規形態
US9884856B2 (en) Crystal form of Dabrafenib mesylate and preparation method thereof
EA036874B1 (ru) Новые соли и полиморфы scy-078
CN117736176A (zh) 雄激素受体拮抗剂的可药用盐及其多晶型物、制备方法和用途
WO2016079313A1 (en) Crystalline forms of afatinib dimaleate
EP4293021A1 (en) Salt of nitrogen-containing fused heterocyclic compound or crystal form thereof, and preparation method therefor, pharmaceutical composition thereof, and use thereof
CN114026088A (zh) Jak2抑制剂的结晶形式
US10150772B2 (en) Crystalline forms of PARP inhibitors
EP2922838B1 (en) Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} .
CN112513026B (zh) Lta4h抑制剂的晶型
RU2845218C2 (ru) Кристаллическая форма гидрата свободного основания лорлатиниба
TW202540110A (zh) 化合物鹽的晶型及其製備方法和用途
CA3170562A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
CA2944150A1 (en) Polymorphic forms and co-crystals of a c-met inhibitor
HK40088128A (en) Salt of compound and pharmaceutical composition containing salt